Table 30CADTH Cost Comparison Table – New Formulation of Vedolizumab

Drug and comparatorStrengthDosage formPrice ($)Recommended doseaAverage annual drug cost ($)Relative difference in annual drug costs ($) compared to new formulation
Year 1 (induction + maint.)Year 2 (maint. only)Year 1 (induction + maint.)Year 2 (maint. only)
New formulation
Vedolizumab SC (Entyvio)108 mg/0.68 mLPre-filled syringe822.5000b300 mg (IV) at weeks 0 and 2, followed by 108 mg (SC) every 2 weeks thereafter26,32021,458——
Reference formulation
Vedolizumab IV (Entyvio)300 mgVial3,290.0000b300 mg at weeks 0, 2, and 6, followed by every 8 weeks thereafter26,32021,4580% (0)0% (0)
Relevant comparators
Adalimumab (Humira)40 mg/0.8 mL; 10 mg/0.1 mL; 20 mg/0.2 mL; 40 mg/0.4 mL; and 80 mg/0.8 mLPre-filled syringe785.4500; NA; 392.7250c;NA; and NA160 mg week 0, 80 mg week 2, followed by 40 mg every 2 weeks thereafter23,56420,492−10.5% (−2,757)−4.50% (−967)
Infliximab (Inflectra)100 mgVial525.00005 mg/kg at weeks 0, 2, and 6, followed by every 8 weeks thereafterd16,80013,697−36.2% (−9,520)−36.2% (−7,762)
Infliximab (Remicade)100 mgVial977.0000c5 mg/kg at weeks 0, 2, and 6, followed by every 8 weeks thereafterd31,26425,48918.8% (4,944)18.8% (4,031)
Infliximab (Renflexis)100 mgVial493.00005 mg/kg at weeks 0, 2, and 6, followed by every 8 weeks thereafterd15,77612,862−40.1% (−10,544)−40.1% (−8,596)
Ustekinumab (Stelara)130 mg/ 26 mLVial2,080.0000c260 mg to 520 mg (IV) depending on body weight followed by 90 mg (SC) every 8 weekse34,118 to 38,27829,9587,798 (29.6%) to 11,958 (45.4%)39.6% (8,499)
45 mg/ 0.5 mL and 90 mg/ 1.0 mLPre-filled syringe or vial4,593.1400

maint. = maintenance; SC = subcutaneous.

Note: All prices are from the Ontario Drug Benefit Formulary (accessed October 2020)18 unless otherwise indicated and do not include dispensing fees. Annual cost calculations based on 365.25 days per year.

a

Based on doses recommended in the appropriate product monographs: adalimumab,14 Infliximab (Inflectra),13 Infliximab (Remicade),12 Infliximab (Renflexis),19 and ustekinumab.15

b

Sponsor’s submitted price.16

c

Saskatchewan drug formulary (accessed October 2020).20

d

Average patient weight of 74.1 kg from VISIBLE 2 trial used to calculate dosage/cost.16 No vial sharing was assumed.

e

For patients weighing up to 55 kg, more than 55 kg up to 85 kg, and more than 85 kg, the recommended initial dosing of ustekinumab IV was 260 mg, 390 mg, and 520 mg, respectively.15

From: Sponsor’s Summary of the Cost Information

Cover of Clinical and Economic Review Report: Vedolizumab (ENTYVIO SC)
Clinical and Economic Review Report: Vedolizumab (ENTYVIO SC): Takeda Canada Inc. Indication: Crohn disease [Internet]
Copyright © 2021 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.